Augmont Enterprises approves Q2 FY27 unaudited financial results

Augmont Enterprises Limited’s Board of Directors, in a meeting held on November 4, 2026, approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a profit for the quarter of ₹1,203.03 million and ₹846.37 million for the consolidated and standalone statements, respectively. Significant approvals also included the appointment of secretarial auditors and revised monetary limits for loans and investments.

Augmont Enterprises Reports Q2 FY27 Financials

Augmont Enterprises Limited announced today that its Board of Directors, at a meeting convened on November 4, 2026, has considered and approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company’s standalone profit for the quarter stood at ₹1,203.03 million, while the consolidated profit for the same period was ₹846.37 million. For the half-year ended September 30, 2026, the standalone profit was ₹1,065.83 million, and the consolidated profit was ₹1,814.77 million.

Key Board Approvals

In addition to the financial results, the Board approved several other important matters. These include:

  • The statement indicating the utilization of the company’s Public Issue proceeds and any deviation or variation thereof.
  • The appointment of M/s. Sanjay Dholakia and Associates as Secretarial Auditors for a five-year term, subject to shareholder approval.
  • Recommendation to shareholders for approval of revised monetary limits for giving loans, guarantees, and making investments under Section 186 of the Companies Act, 2013.
  • Recommendation for approval of entering into material related party transactions.
  • Recommendation for the ratification of the pre-IPO Augmont Enterprises Limited ESOP Plan – 2025, including eligible employees of subsidiary companies.

The Board meeting commenced at 05:30 p.m. and concluded at 06:31 p.m.

Source: BSE

Previous Article

Balkrishna Industries Ltd. outlines growth roadmap and FY27 highlights

Next Article

KIMS Hospitals reports ₹150 crore raised from warrants in Q2 FY27